Abstract: Tyrosine kinase inhibitors (TKIs) can significantly improve the overall survival rate of patients with gastrointestinal stromal tumor (GIST), but the side effects affect the dose intensity and treatment compliance of patients, thus affecting the clinical efficacy. In 2018, the Chinese Society of Surgeons for Gastrointestinal Stromal Tumor of the Chinese Medical Doctor Association organized clinical experts involving in management of side effects of GIST targeted drugs, based on clinical evidences and experiences, to formulate the first of Chinese consensus on management of tyrosine kinase inhibitor‑associated side effects in gastrointestinal stromal tumors. With the popularization of clinical application of TKIs and the deepening understanding of their side effects, especially the new type of TKIs drugs added to drug pipeline of GIST in recent years, the Chinese Society of Surgeons for Gastrointestinal Stromal Tumor of the Chinese Medical Doctor Association organize experts to revise, update and formulate the Chinese expert consensus on management of tyrosine kinase inhibitor‑associated side effects in gastrointestinal stromal tumor (2022 edition), in order to guide the early warning and treatment of TKIs‑associated side effects in clinical practice.